LPCAT1 overexpression promotes the progression of hepatocellular carcinoma

Table 1 Potential therapeutic agents for hepatocellular carcinoma by targeting LPCAT1’s regulatory network

Rank	Cmap name	Cell line	Description	Chemical formula	Enrichment	P	Specificity	Anti-cancer	Anti-HCC
1	LY-294002	MCF7	Specific inhibitor of phosphatidylinositol 3-kinase	C19H17NO3	− 0.437	< 0.0001	0.17	√	√
2	Trichostatin A	PC3	Histone deacetylase 3 inhibitor	C17H22N2O3	− 0.366	< 0.0001	0.53	√	√
3	Trichostatin A	MCF7	Histone deacetylase 3 inhibitor	C17H22N2O3	− 0.307	< 0.0001	0.67	√	√
4	Sirolimus	MCF7	An immunosuppressant which possesses both antifungal and antineoplastic properties	C51H79NO13	− 0.395	< 0.001	0.36	√	√
5	Tomatidine	MCF7	/	/	− 0.982	< 0.001	0	√	/
6	Pyridoxine	MCF7	The 4-methanol form of vitamin B6	C8H11NO3	− 0.981	< 0.001	0.01	√	/
7	Vorinostat	MCF7	A drug currently under investigation for the treatment of cutaneous T cell lymphoma	C14H20N2O3	− 0.673	< 0.01	0.28	√	√
8	Meticrane	PC3	Diuretic medication	C10H13NO4S2	− 0.976	< 0.01	0	/	/
9	Harmine	MCF7	/	C13H12N2O	− 0.972	< 0.01	0.01	√	√
10	Tanespimycin	MCF7	A small molecule inhibitor of heat shock protein 90 (HSP90), which is developed for the treatment of several types of cancer, solid tumours or chronic myelogenous leukemia	C31H43N3O8	− 0.305	< 0.01	0.49	√	√

ISSN: 1475-2867